A Bayesian latent-subgroup platform design for dose optimization
From MaRDI portal
Cites work
- scientific article; zbMATH DE number 2242805 (Why is no real title available?)
- A Bayesian adaptive phase i/II platform trial design for pediatric immunotherapy trials
- A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications
- A Bayesian phase I/II trial design for immunotherapy
- A Strategy for Dose-Finding and Safety Monitoring Based on Efficacy and Adverse Outcomes in Phase I/II Clinical Trials
- A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies
- A utility-based Bayesian phase I--II design for immunotherapy trials with progression-free survival end point
- A weakly informative default prior distribution for logistic and other regression models
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Bayesian Measures of Model Complexity and Fit
- Dose-Finding Based on Efficacy-Toxicity Trade-Offs
- On the likelihood that one unkrown probability exeeds another in view of the evidence of two samples.
- STEIN: a simple toxicity and efficacy interval design for seamless phase I/II clinical trials
- Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes
- Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
This page was built for publication: A Bayesian latent-subgroup platform design for dose optimization
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q7029596)
